Dulaglutide, liraglutide and subcutaneous semaglutide have been approved for reducing the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus with established cardiovascular disease, dulaglutide is approved for use in type 2 diabetes mellitus with multiple risk factors, and both liraglutide and semaglutide have been approved for chronic weight management
Follow-up visits are scheduled weekly, bi-weekly, or monthly depending on your needs
The small human studies should be treated as signal-generating, not definitive
ProbioticsBeneficial bacteria that maintain a healthy gut microbiome
The guidelines assume some exposure, not constant exposure
Considerations : Typically compounded, off-label as its not yet FDA-approved